Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/94960
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Author: Soverini, S.
Branford, S.
Nicolini, F.E.
Talpaz, M.
Deininger, M.W.N.
Martinelli, G.
Müller, M.C.
Radich, J.P.
Shah, N.P.
Citation: Leukemia Research, 2014; 38(1):10-20
Publisher: Elsevier
Issue Date: 2014
ISSN: 0145-2126
1873-5835
Statement of
Responsibility: 
Simona Soverini, Susan Branford, Franck E. Nicolini, Moshe Talpaz, Michael W.N. Deininger, Giovanni Martinelli, Martin C. Müller, Jerald P. Radich, Neil P. Shah
Abstract: Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations.
Keywords: BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations
Rights: © 2013 The Authors. Published by Elsevier Ltd. Open access CC BY-NC-SA 3.0
DOI: 10.1016/j.leukres.2013.09.011
Published version: http://dx.doi.org/10.1016/j.leukres.2013.09.011
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_94960.pdfPublished version890.67 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.